secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001104659-25-080304
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance's Amtagvi receives Health Canada approval for advanced melanoma
-----------------------------------------------------------------------

- Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.
- First marketing authorization outside the U.S.; first T cell therapy approved for a solid tumor cancer in Canada.
- Approval based on Phase 2 C-144-01 trial ORR and DOR by IRC; results published in 2022 and 2025 journals.
- Iovance expects to authorize first Canadian treatment center within next few months; advancing ex-U.S. strategy.
- Amtagvi is also being investigated in frontline advanced melanoma (Phase 3 TILVANCE-301) and other solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925080304/0001104659-25-080304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925080304/tm2523802d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-080304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer